resistanceBio has built the first cancer treatment resistance system to predict how multiple cancer types will respond to approved or novel treatments. The ResCu platform aims only to advance therapies that have the potential to be superior to the standard of care and significantly extend patients’ lives. ResCu addresses the root cause of treatment failure, which is treatment resistance.



Operations

resistanceBio

Cantos Ventures is a pre-seed and seed-stage venture capital fund that invests in startups in 'pre-inflection' industries. We view every startup as a journey, and seek to join those with noble aims.

Your story awaits